Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

February 17, 2020February 17, 2020

Nearly 40% of IPF Patients in US Not Prescribed Esbriet or Ofev Despite Effectiveness, Study Reports

News

In the U.S., 61% of people with idiopathic pulmonary fibrosis (IPF) are prescribed approved anti-fibrotic therapies, namely Ofev (nintedanib) and Esbriet (pirfenidone), analysis of data from the U.S. Pulmonary Fibrosis (PF) ... Read more

January 29, 2020January 29, 2020

Telomeres Shortening in IPF May Occur Before Disease Onset, Study Suggests

News

People with idiopathic pulmonary fibrosis have shorter telomeres — the protective caps at the end of chromosomes — but shortening may occur prior to disease onset. The study with that ... Read more

January 22, 2020January 22, 2020

Antibiotic Azithromycin Lessens Fibrosis, Promotes Death of IPF Fibroblasts, Study Reports

News

The antibiotic azithromycin (AZT), frequently prescribed for fighting bacterial infections, has anti-fibrotic effects and promotes the death of fibroblasts — cells promoting fibrosis, or scarring — in people with ... Read more

January 3, 2020January 3, 2020

Model of Pulmonary Fibrosis Details Gene Changes at Specific Disease Stages, Study Reports

News

A model of the human lung constructed with the help of tissue samples from 10 idiopathic pulmonary fibrosis (IPF) patients details changes in gene activity that precede evident fibrosis, a ... Read more

November 12, 2019November 13, 2019

Occupational Dust Exposure May Not Hinder Effectiveness of Anti-fibrotic Therapies, Study Suggests

News

Exposure to dust in the workplace for 10 years or longer seems to have no detrimental effect on the response of patients with idiopathic pulmonary fibrosis (IPF) to anti-fibrotic ... Read more

October 28, 2019October 28, 2019

Lung Cancer Patients with IPF and Emphysema at Higher Risk of Flares, Study Says

News

People with non-small cell lung cancer (NSCLC) who also have pulmonary fibrosis and emphysema are at a greater risk of acute flares following cancer treatment that includes chemotherapy, surgery, ... Read more

October 15, 2019October 15, 2019

NIH Director’s New Innovator Award Funds Research to Develop New Models to Study IPF

News

April Kloxin, PhD, has received the 2019 National Institutes of Health (NIH) Director’s New Innovator Award to develop next-generation materials and tools to help accelerate research on idiopathic pulmonary fibrosis (IPF). ... Read more

September 20, 2019September 25, 2019

Citryll, Lonza Team up to Develop Antibody for Pulmonary Fibrosis, Other Inflammatory Diseases

News

Citryll and Lonza have teamed up to develop Citryll’s candidate antibody, called CIT-013, as a therapy for inflammatory diseases, including idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis, the companies ... Read more

September 4, 2019September 4, 2019

Protein on Surface of Immune Cells May Drive Inflammation in Pulmonary Fibrosis, Study Suggests

News

Immune cells can sense the mechanical forces at work in the lungs via a gate called PIEZO1, and deleting this gene in immune cells led to worse lung infections, ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Nearly 40% of IPF Patients in US Not Prescribed Esbriet or Ofev Despite Effectiveness, Study Reports

Telomeres Shortening in IPF May Occur Before Disease Onset, Study Suggests

Antibiotic Azithromycin Lessens Fibrosis, Promotes Death of IPF Fibroblasts, Study Reports

Top 10 Pulmonary Fibrosis Stories of 2019

Model of Pulmonary Fibrosis Details Gene Changes at Specific Disease Stages, Study Reports

Occupational Dust Exposure May Not Hinder Effectiveness of Anti-fibrotic Therapies, Study Suggests

Lung Cancer Patients with IPF and Emphysema at Higher Risk of Flares, Study Says

NIH Director’s New Innovator Award Funds Research to Develop New Models to Study IPF

Citryll, Lonza Team up to Develop Antibody for Pulmonary Fibrosis, Other Inflammatory Diseases

Protein on Surface of Immune Cells May Drive Inflammation in Pulmonary Fibrosis, Study Suggests

Pin It on Pinterest